Autophagy Does Not Contribute to TKI Response in a Imatinib-resistant Chronic Myeloid Leukemia Cell Line
Autophagy is an evolutionarily conserved cellular process in which components of the cytoplasm are delivered to lysosomes for degradation and has been proposed to play a role in imatinib resistance in chronic myeloid leukemia cells. Chronic myeloid leukemia is a clonal myeloproliferative disorder arising from the neoplastic transformation of the hematopoietic stem cell. We used a Bcr-Abl-independent and imatinib-resistant K562 subpopulation (K562-IR) that we generated earlier in our laboratory for this study. We showed that in the presence of imatinib autophagy was triggered via LC3I/II transformation, p62 protein expression and acidic vacuoles accumulation in tyrosine kinase inhibitor-sensitive K562 cells; whereas in the cell line K562-IR which is imatinib-resistant and Bcr-Abl independent, autophagy is not triggered. With ongoing research and trails to combine tyrosine kinase inhibitors with autophagy inhibitors, our results suggest a model of resistance in which treatment with a TKI inhibitor does not increase autophagy, basically because its presence does not cause cellular stress due to Bcr-Abl signaling not being required for survival.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:55 |
|---|---|
| Enthalten in: |
Molekuliarnaia biologiia - 55(2021), 4 vom: 25. Juli, Seite 626-633 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Baykal-Köse, S [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
8A1O1M485B |
|---|
| Anmerkungen: |
Date Completed 27.08.2021 Date Revised 27.08.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.31857/S0026898421040042 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM329759434 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM329759434 | ||
| 003 | DE-627 | ||
| 005 | 20231225205823.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.31857/S0026898421040042 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1099.xml |
| 035 | |a (DE-627)NLM329759434 | ||
| 035 | |a (NLM)34432780 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Baykal-Köse, S |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Autophagy Does Not Contribute to TKI Response in a Imatinib-resistant Chronic Myeloid Leukemia Cell Line |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.08.2021 | ||
| 500 | |a Date Revised 27.08.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Autophagy is an evolutionarily conserved cellular process in which components of the cytoplasm are delivered to lysosomes for degradation and has been proposed to play a role in imatinib resistance in chronic myeloid leukemia cells. Chronic myeloid leukemia is a clonal myeloproliferative disorder arising from the neoplastic transformation of the hematopoietic stem cell. We used a Bcr-Abl-independent and imatinib-resistant K562 subpopulation (K562-IR) that we generated earlier in our laboratory for this study. We showed that in the presence of imatinib autophagy was triggered via LC3I/II transformation, p62 protein expression and acidic vacuoles accumulation in tyrosine kinase inhibitor-sensitive K562 cells; whereas in the cell line K562-IR which is imatinib-resistant and Bcr-Abl independent, autophagy is not triggered. With ongoing research and trails to combine tyrosine kinase inhibitors with autophagy inhibitors, our results suggest a model of resistance in which treatment with a TKI inhibitor does not increase autophagy, basically because its presence does not cause cellular stress due to Bcr-Abl signaling not being required for survival | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CML | |
| 650 | 4 | |a TKI resistance | |
| 650 | 4 | |a autophagy | |
| 650 | 4 | |a chronic myeloid leukemia | |
| 650 | 4 | |a imatinib | |
| 650 | 7 | |a Imatinib Mesylate |2 NLM | |
| 650 | 7 | |a 8A1O1M485B |2 NLM | |
| 700 | 1 | |a Efe, H |e verfasserin |4 aut | |
| 700 | 1 | |a Yüce, Z |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Molekuliarnaia biologiia |d 1975 |g 55(2021), 4 vom: 25. Juli, Seite 626-633 |w (DE-627)NLM000033979 |x 0026-8984 |7 nnns |
| 773 | 1 | 8 | |g volume:55 |g year:2021 |g number:4 |g day:25 |g month:07 |g pages:626-633 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.31857/S0026898421040042 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 55 |j 2021 |e 4 |b 25 |c 07 |h 626-633 | ||